Prevalence of diabetes mellitus and altered fasting blood glucose at the time of pancreatic cancer diagnosis, in a group of patients assisted in a gastroenterological referral center in Argentina

Authors

  • Ana Florencia Costa Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Autonomous City of Buenos Aires, Argentina
  • Andrea La Cava Barceló Foundation, Autonomous City of Buenos Aires, Argentina
  • María Mercedes Mon Ratti Barceló Foundation, Autonomous City of Buenos Aires, Argentina
  • Julieta Nosetto Barceló Foundation, Autonomous City of Buenos Aires, Argentina
  • Marcela Carballido Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Autonomous City of Buenos Aires, Argentina
  • María Amelia Linari Barceló Foundation, Autonomous City of Buenos Aires, Argentina
  • Velia Löbbe Barceló Foundation, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v55i1.471

Keywords:

diabetes mellitus, ductal adenocarcinoma of the pancreas, impaired fasting blood glucose, prevalence

Abstract

Introduction: diabetes mellitus (DM) is considered to be a risk factor for the development of pancreatic ductal adenocarcinoma (PDAC).

Objectives: describe the prevalence of DM and of impaired fasting glucose (IFG) at the diagnosis of PDAC, among patients assisted in a gastroenterological reference center. Analyze differences in personal and nutritional characteristics in patients with both PDAC and DM; with both PDAC and IFG; and with PDAC but neither DM nor IFG. Determine the time lapse between the diagnosis of DM and the diagnosis of PDAC.

Materials and methods: between October 2019 and March 2020, we analyzed 465 clinical records of PDAC-diagnosed patients over 18 years, from Oncology and Nutrition Sections.

Results: 171 clinical records (36.7%) showed both PDAC and DM; 294 clinical records (63.2%) showed PDAC but not DM. In 45.1% of the former, the interval between the diagnosis of DM and that of PDAC was <1 year, and in 17.65%, 15.69% and 21.57%, the lapses corresponded to 1 and 5 years, between 5 and 10 years y >10 years, respectively.

Conclusions: the prevalence of DM in ACDP was higher than that registered in the general population (37% vs 12.7%), being 45.10% when it presented within the first year of oncological diagnosis. Our results agree with the international bibliography that relates recently diagnosed DM as a factor associated with the presence of ACDP due to shared risk factors, physiopathological variables of DM or as a consequence of its pharmacological therapy.

Author Biographies

Ana Florencia Costa, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Autonomous City of Buenos Aires, Argentina

Nutrition specialist career, Faculty of Medicine, Barceló Foundation, Nutrition Unit, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo

Andrea La Cava, Barceló Foundation, Autonomous City of Buenos Aires, Argentina

Nutrition specialist career

María Mercedes Mon Ratti, Barceló Foundation, Autonomous City of Buenos Aires, Argentina

Nutrition specialist career

Julieta Nosetto, Barceló Foundation, Autonomous City of Buenos Aires, Argentina

Nutrition specialist career, Faculty of Medicine

Marcela Carballido, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Autonomous City of Buenos Aires, Argentina

Staff Physician

María Amelia Linari, Barceló Foundation, Autonomous City of Buenos Aires, Argentina

Nutrition specialist career

Velia Löbbe, Barceló Foundation, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Autonomous City of Buenos Aires, Argentina

Nutrition specialist career, Faculty of Medicine, Barceló Foundation, Nutrition Unit, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo

References

I. Instituto Nacional de Estadística y Censos. Secretaría de Gobierno de la Salud. Cuarta Encuesta Nacional de Factores de Riesgo: resultados preliminares. 1º Ed. Ciudad Autónoma de Buenos Aires, 2019. Libro digital, PDF Archivo Digital. Indicadores de Salud. 2. Calidad de la Atención de Salud .3. Acceso a la Salud. I. Título. CDD 613. Disponible en: https://www.indec.gob.ar/ftp/cuadros/publicaciones/enfr_2018_resultados_preliminares.pdf.

II. Ballesteros I, Abriata MG. Análisis de situación de salud por cáncer. Argentina, 2018. Instituto Nacional del Cáncer. Ministerio de Salud. Boletín de vigilancia epidemiológica. Disponible en: http://www.msal.gob.ar/images/stories/bes/graficos/0000001386cnt-20181213-boletin-epidemiologia.pdf.

III. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20 (10):1218-49.

IV. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR, 2007. Disponible en: https://discovery.ucl.ac.uk/id/eprint/4841/1/4841.pdf

V. Heidemann C, Boeing H, Pischon T, Nôthlings U, Joost HG, SAchulze MB. Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: a prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort. Eur J Epidemiol 2009; 24 (6): 281-8.

VI. Ben Q, Cai Q, Li Z, Yuan Z, Deng S, Wang K. The relationship between newonset diabetes mellitus and pancreatic cancer risk: A case-control study. Eur J Cáncer 2011; 48:248-54.

VII. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4 (3): 369-80.

VIII. American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes 2019. Diabetes Care 2019; 42(Supp 1): S34-S45.

IX. Andersen D, Korc M, Petersen G, Eibl G, Li D. Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes 2017; 66:1103-10.

X. Li D, Tang H, Hassan M., Holly E, Bracci P, Silverman T. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22 (2):189-97.

XI. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 2013; 42: 198-201.

XII. Chari ST, Leibson CL, Rabe KG, Ransom J, De Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129:504-511.

XIII. Sharma A, Kandlakunta H, Singh Nagpal SJ, Ziding F, Hoos W, Petersen GM, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes. Gastroenterology 2018; 155 (3):730-739.

XIV. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. 2013; 42: 198-201.

XV. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30.

XVI. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 2018; 18:688-98.

XVII. McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol 2018; 24 (43):4846-4861.

XVIII. International Agency for Research on Cancer. World Health Organization. Global Cancer Observatory 2018. Disponible en: http://gco.iarc.fr/.

XIX. Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: A review. Cancer Lett 2016; 381:269-277.

XX. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update on familiar pancreatic cancer. Adv Surg 2010; 44:293-311.

XXI. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995; 273:1605-9.

XXII. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British Journal of Cancer 2005; 92:2076-83.

XXIII. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. European Journal of Cancer 2011; 47:1928-37.

XXIV. Li D, Tang H, Hassan M, Holly E, Bracci P, Silverman T. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case control studies. Cancer Causes Control 2011; 22(2):189-97.

XXV. Sadr-Azodi O, Gudbjörnsdottir S, Ljung R. Pattern of increasing HbA1c levels in patients with diabetes mellitus before clinical detection of pancreatic cancer a population based nationwide case-control study. Acta Oncol 2015; 54 (7): 986-92.

XXVI. Pothuraju R, Rachagani S, Junker WM, Chaudhary S, Saraswathi V, Kaur S et al. Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting. Journal of Experimental & Clinical Cancer Research 2018; 37:319-33.

XXVII. Isaksson B, Strommer L, Friess H, Buchler MW, Herrington MK, Wang F, et al. Impaired insulin action on phosphatidylinositol 3-kinase activity and glucose transport in skeletal muscle of pancreatic cancer patients. Pancreas 2003; 26 (2):173-7.

Published

2021-04-01

How to Cite

Costa, A. F., La Cava, A., Mon Ratti, M. M., Nosetto, J., Carballido, M., Linari, M. A., & Löbbe, V. (2021). Prevalence of diabetes mellitus and altered fasting blood glucose at the time of pancreatic cancer diagnosis, in a group of patients assisted in a gastroenterological referral center in Argentina. Journal of the Argentine Society of Diabetes, 55(1), 27–34. https://doi.org/10.47196/diab.v55i1.471

Issue

Section

Original article

Most read articles by the same author(s)

1 2 > >>